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variety of sources: health professionals, patients, and 
private and third-sector organisations. We need our call 
to be echoed and spread through existing networks to 
maximise the range of contributors. Contributions should 
be sent to the website of the Lancet UK Policy Matters.
Lancet UK Policy Matters aims to increase transparency 
and awareness about important policy issues, to 
encourage debate, and gather early information on the 
impact of changes in health policy. It is our hope that 
Lancet UK Policy Matters will make a valuable contribution 
to the debate surrounding the government’s current 
“listening exercise” on NHS modernisation, and faciliate 
better evidence for better health policy in the future. Only 
through better evidence can we hold governments to 
account for the impact that their policies have on health.
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Science as a public enterprise: the case for open data
The past half-century has seen a breathtaking surge 
in scientiﬁ c discovery. We have put satellites into 
orbit and probed the universe; we have discovered the 
chemical structure of living organisms and learned to 
manipulate it; we have been able to read the Earth’s 
history in minute detail from ice-sheet and ocean 
cores; and we have improved human and animal 
health through increasingly large epidemiological 
studies and clinical trials. All of these achievements 
have necessitated new ways of collecting, storing, 
manipulating, and transmitting information that 
far surpass anything previously dreamed of. The 
information technology that permits this has not only 
removed geographical barriers but also put immense 
power to access, manipulate, and communicate 
information (including scientiﬁ c data) in the hands of 
ordinary citizens.
Yet many of the habits of scientists have barely 
changed since the 18th century. Driven by curiosity, 
they have typically pursued their research, published 
their ﬁ ndings, usually in peer-reviewed journals, ﬁ led 
their data, and then moved on. But such detachment 
is now questionable as science profoundly changes the 
lives of citizens, and scientists collect more and more 
evidence of the human assault on the natural systems of 
the planet. Science has become woven into the fabric of 
modern civilisation and should be, and be seen to be, a 
public enterprise, not a private enterprise done behind 
closed laboratory doors.
Despite the spectacular advances of science, there is an 
emerging undercurrent of criticism about the accessibility 
of data on which scientists base their conclusions and on 
which policy or regulatory decisions are made. Scientists 
have tended to regard their data as personal property. 
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After all, it is they who worked hard to generate it—and 
ownership has never been seriously challenged. But there 
are now strong reasons for a much more open attitude 
to data. First, technology has made computer code and 
large datasets more important to science and has opened 
up the prospect of sharing code and data at the click of 
a mouse. Second, there is public interest in making data 
available to other scientists to validate ﬁ ndings or re-use 
the data in new ways to advance knowledge.1,2 Third, 
much modern science is created using public funds, 
which should oblige scientists to maximise the utility 
of their ﬁ ndings for the public good. And last, but by 
no means least, there are many competent members of 
the public who wish to test for themselves some of the 
pronouncements of scientists by analysing the data on 
which such pronouncements are based.
Conventional peer-reviewed publications generally 
provide summaries of the available data, but not 
eﬀ ective access to data in a useable format. Increasing 
calls for greater accessibility have not only come from 
peer reviewers and those who wish data to be more 
eﬃ  ciently used,3,4 but also from citizens who wish to 
interrogate scientiﬁ c conclusions in depth.5 The latter 
in particular have often been frustrated by the apparent 
resistance of scientists to the release of data, and are 
increasingly making use of freedom of information laws 
to obtain it. Recent high-proﬁ le cases in the UK include 
the global temperature data sought from the University 
of East Anglia,6 which culminated in the so-called 
Climategate aﬀ air, and the tree-ring data series eventually 
obtained from Queen’s University Belfast through the 
intervention of the Information Commissioner.7
Biomedical scientists have a mixed track record in 
relation to transparency and data-sharing. On the one 
hand the principles agreed at the genome-sequencing 
meeting8 in Bermuda, in 1997, paved the way for open 
data-sharing among the genome science community. On 
the other hand, persistent failures to place even summary 
results of clinical trials in the public domain have led to 
publication bias that seriously undermines those seeking 
to undertake systematic reviews.9,10 The value of routinely 
sharing the results of clinical trials would be immense. 
The meta-analysis of the raw data from clinical trials of 
the eﬀ ects of aspirin in the prevention of cardiovascular 
disease including—as it did—data from 95 000 patients is 
a ﬁ ne example of the beneﬁ ts of data-sharing.11 With the 
increasing use of electronic medical records, there is the 
opportunity for anonymised data from routine clinical 
use of drugs to provide high quality pharmacovigilance 
on a hitherto unprecedented scale.
A regime of open access to scientiﬁ c data does, 
however, pose problematic questions (panel). Because 
of the importance and timeliness of the issues, the UK’s 
Royal Society has established a Working Group to explore 
them in depth and to make recommendations about 
how they might be addressed. The Working Group now 
seeks evidence from scientists and from the public.12 We 
badly need to get this right!
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Panel: Issues for open data sharing
Cost–beneﬁ t
Making scientiﬁ c data publicly available would be expensive. 
Who would (or should) pay? To what extent would this eat 
into the funding of primary research, and would it be 
compensated for by greater eﬃ  ciency in the research system? 
Is the potential for misuse, misinterpretation, and the 
triggering of spurious ﬁ ndings from data a price worth 
paying for greater openness?
Triggering and timing
How and when should data release be triggered and how 
should data quality be assured? Should scientists be permitted 
to publish their own analysis and conclusions before releasing 
data to others? What about data that are never published?
Whose data?
Should open release only apply to those in receipt of grants 
from or employed by public funds? What about data from 
clinical trials, or data from safety analyses by private 
companies used to inform decisions of legitimate public 
interest (eg, Deep Water Horizon and Fukushima)?
Conﬁ dentiality, privacy, security, and intellectual property
How should we cope with the need for conﬁ dentiality, 
anonymisation, and data security? How would intellectual 
property rights be protected? How should we balance 
personal privacy against wider public beneﬁ t?
International
Unless scientists from all jurisdictions allowed their data to be 
shared, would data-sharing have any real traction or meaning?
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Although stillbirth is an issue in low-income countries 
because of many factors associated with poverty, 
such as access to basic obstetric care, it is also a public 
health priority in high-income countries. In the USA, 
the stillbirth rate is 6·2 per 1000 deliveries at 20 weeks’ 
gestation or greater, aﬀ ecting 25 894 fetuses in 2005;1 
a number similar to the 28 384 infant deaths in 2005.2 
A substantial component of the public health burden 
in high-income countries is disparity according to 
race and ethnic origin. Stillbirth rates in non-Hispanic 
black people in the USA are nearly double, at 11·1 per 
1000 deliveries, the 4·8 per 1000 for non-Hispanic white 
people and 5·4 per 1000 for Hispanic people.1 Despite 
attempts to identify factors to explain this diﬀ erence, 
the complexity of interactions between contributing 
factors hinders eﬀ orts to explain the disparity and to 
design and implement eﬀ ective interventions to narrow 
the gap.
Even with national databases in place for surveillance, 
the data available for establishing causes of, and 
contributing factors for, stillbirth are inadequate. In the 
USA, the National Vital Statistics System is based on 
birth certiﬁ cates, death certiﬁ cates, and reports of fetal 
death that have been ﬁ led in state vital-statistics oﬃ  ces. 
A limitation of the system is that deﬁ nitions of stillbirth 
vary by state, resulting in inconsistent reporting and 
misclassiﬁ cation. Completion of forms and quality of 
data vary, including in reporting of education, Hispanic 
ethnic origin, adverse health behaviours, and medical 
and pregnancy complications. Although eﬀ orts are 
being made to improve assignment of cause of death, 
no national database exists for cause. Furthermore, non-
uniform stillbirth evaluations, with fetal post-mortem 
examination, placental pathology, and maternal and 
fetal testing of variable quality and possibly incomplete 
when the fetal death certiﬁ cate is ﬁ nalised, and lack of 
a standard classiﬁ cation system limit the usefulness of 
the data. Eﬀ orts to standardise classiﬁ cation systems 
internationally,3 comprehensive studies on causes of 
stillbirth that go beyond the information gathered by 
the national vital-statistics system,4 and uniform use of 
electronic medical records will help our understanding.
Overall, most of the disparity in the USA presently 
cannot be explained, although the contribution of 
certain factors, such as speciﬁ c maternal medical 
problems, variation by gestational age, and socio-
economic diﬀ er ences, have been studied. Speciﬁ c 
maternal disorders such as chronic hypertension, 
dia betes, autoimmune disorders, and obe sity are 
more common in non-Hispanic black women than in 
others, and result in higher rates of pre-eclampsia and 
abruption, leading to increased rates of stillbirth.5,6 The 
greatest disparity in stillbirth risk between non-Hispanic 
black and white women is in previable deliveries, 
at 20–23 weeks’ gestation, decreasing as gestation 
progresses until 41 weeks.7 The rate of stillbirths 
at 20–27 weeks’ gestation has remained unchanged 
since 1990,1 and is associated with an increased 
occurrence of maternal infection.8 The contributions 
of these associations to the disparity have not been 
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